Treatment algorithms in Crohn's - Up, down or something else?

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 3, 2014, Pages 473-483

  Antunes, Ophélie ^a   Filippi, Jérôme ^a   Hébuterne, Xavier ^a   Peyrin Biroulet, Laurent ^b  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Anti TNF; Crohn's disease; Mucosal healing; Step up; Top down

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ALGORITHM; ARTICLE; CANCER RISK; CROHN DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MULTICENTER STUDY (TOPIC); MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NON MELANOMA SKIN CANCER; PATIENT MONITORING; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN CANCER; TREATMENT OUTCOME;

ANTI-TNF; CROHN'S DISEASE; MUCOSAL HEALING; STEP-UP; TOP-DOWN;

6-MERCAPTOPURINE; ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; POLYETHYLENE GLYCOLS; PRACTICE GUIDELINES AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902286149     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.05.001     Document Type: Review

References (67)

1. H.M. Van Dullemen, S.J. van Deventer, D.W. Hommes, H.A. Bijl, J. Jansen, and G.N. Tytgat et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology 109 1995 129 135
2. W. Reinisch, W.J. Sandborn, P. Rutgeerts, B.G. Feagan, D. Rachmilewitz, and S.B. Hanauer et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies Inflamm Bowel Dis 18 2012 201 211
3. S.B. Hanauer, B.G. Feagan, G.R. Lichtenstein, L.F. Mayer, S. Schreiber, and J.F. Colombel et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 2002 1541 1549
4. W.J. Sandborn, S.B. Hanauer, P. Rutgeerts, R.N. Fedorak, M. Lukas, and D.G. MacIntosh et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial Gut 56 2007 1232 1239
5. W.J. Sandborn, B.G. Feagan, S. Stoinov, P.J. Honiball, P. Rutgeerts, and D. Mason et al. Certolizumab pegol for the treatment of Crohn's disease N Engl J Med 357 2007 228 238
6. W.J. Sandborn, M.T. Abreu, G. D'Haens, J.-F. Colombel, S. Vermeire, and K. Mitchev et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 8 2010 688-695.e2
7. B.G. Feagan, R. Panaccione, W.J. Sandborn, G.R. D'Haens, S. Schreiber, and P.J. Rutgeerts et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study Gastroenterology 135 2008 1493 1499
8. L. Peyrin-Biroulet, W. Reinisch, J.-F. Colombel, G.J. Mantzaris, A. Kornbluth, and R. Diamond et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial Gut 63 2014 88 95
9. W.J. Sandborn, S. Hanauer, G. Van Assche, J. Panés, S. Wilson, and J. Petersson et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases J Crohns Colitis 2014 Apr 5 pii: S1873-9946(14)00090-7. http://dx.doi.org/10.1016/j.crohns.2014.02.021. [Epub ahead of print]
10. L. Peyrin-Biroulet, M. Ferrante, F. Magro, S. Campbell, D. Franchimont, and H. Fidder et al. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease J Crohns Colitis 5 2011 477 483
11. G. Bouguen, and L. Peyrin-Biroulet Surgery for adult Crohn's disease: what is the actual risk? Gut 60 2011 1178 1181
12. L. Peyrin-Biroulet, W.S. Harmsen, W.J. Tremaine, A.R. Zinsmeister, W.J. Sandborn, and E.V. Loftus Jr. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004) Am J Gastroenterol 107 2012 1693 1701
13. L. Peyrin-Biroulet, A. Oussalah, N. Williet, C. Pillot, L. Bresler, and M.-A. Bigard Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease Gut 60 2011 930 936
14. P.L. Lakatos, P.A. Golovics, G. David, T. Pandur, Z. Erdelyi, and A. Horvath et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009 Am J Gastroenterol 107 2012 579 588
15. A.V. Ramadas, S. Gunesh, G.A.O. Thomas, G.T. Williams, and A.B. Hawthorne Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates Gut 59 2010 1200 1206
16. G.J. Mantzaris, A. Christidou, M. Sfakianakis, A. Roussos, S. Koilakou, and K. Petraki et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease Inflamm Bowel Dis 15 2009 375 382
17. S. Candy, J. Wright, M. Gerber, G. Adams, M. Gerig, and R. Goodman A controlled double blind study of azathioprine in the management of Crohn's disease Gut 37 1995 674 678
18. J. Rhodes, D. Bainton, P. Beck, and H. Campbell Controlled trial of azathioprine in Crohn's disease Lancet 2 1971 1273 1276
19. N. Chande, D.J. Tsoulis, and J.K. MacDonald Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease Cochrane Database Syst Rev 4 2013 CD000545
20. J. Panés, A. López-SanRomán, F. Bermejo, V. García-Sánchez, M. Esteve, and Y. Torres et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease Gastroenterology 145 2013 766-774.e1
21. J. Cosnes, A. Bourrier, D. Laharie, S. Nahon, Y. Bouhnik, and F. Carbonnel et al. Early administration of azathioprine vs conventional management of Crohn's disease: a randomized controlled trial Gastroenterology 145 2013 758-765.e2
22. P.L. Lakatos, and L. Peyrin-Biroulet Azathioprine in early Crohn's disease: time to revisit patient selection and end points for clinical trials and/or azathioprine efficacy? Gastroenterology 146 2014 867 868
23. L. Beaugerie, N. Brousse, A.M. Bouvier, J.F. Colombel, M. Lémann, and J. Cosnes et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study Lancet 374 2009 1617 1625
24. L. Peyrin-Biroulet, K. Khosrotehrani, F. Carrat, A. Bouvier, J. Chevaux, and T. Simon et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease Gastroenterology 141 2011 1621-1628.e5
25. A. Lopez, M. Mounier, A.-M. Bouvier, F. Carrat, M. Maynadié, and L. Beaugerie et al. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease Clin Gastroenterol Hepatol 2014 Feb 26 pii: S1542-3565(14)00311-5. http://dx.doi.org/10.1016/j.cgh.2014.02.026. [Epub ahead of print]
26. D. Laharie, J. Seneschal, T. Schaeverbeke, M.-S. Doutre, M. Longy-Boursier, and J.-L. Pellegrin et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study J Hepatol 53 2010 1035 1040
27. N. Khan, A.M. Abbas, N. Whang, L.A. Balart, L.A. Bazzano, and T.N. Kelly Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials Inflamm Bowel Dis 18 2012 359 367
28. R. Conway, C. Low, R.J. Coughlan, M.J. O'Donnell, and J.J. Carey Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials Arthritis Rheumatol Hob N. J 66 2014 803 812
29. F. Rondon, O. Mendez, N. Spinel, C. Ochoa, C. Saavedra, and E. Penaranda et al. Methotrexate-induced pulmonary toxicity in psoriatic arthritis (PsA): case presentation and literature review Clin Rheumatol 30 2011 1379 1384
30. N. D'Andrea, L. Triolo, G. Margagnoni, A. Aratari, and C.M. Sanguinetti Methotrexate-induced pneumonitis in Crohn's disease. Case report and review of the literature Multidiscip Respir Med 5 2010 312 319
31. B.G. Feagan, R.N. Fedorak, E.J. Irvine, G. Wild, L. Sutherland, and A.H. Steinhart et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease N Engl J Med 342 2000 1627 1632
32. B.G. Feagan, J. Rochon, R.N. Fedorak, E.J. Irvine, G. Wild, and L. Sutherland et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's study group Investigators N Engl J Med 332 1995 292 297
33. C. Gower-Rousseau, G. Savoye, J.-F. Colombel, and L. Peyrin-Biroulet Are we improving disease outcomes in IBD? A view from the epidemiology side Gut 2013 Nov 28 http://dx.doi.org/10.1136/gutjnl-2013-306045. [Epub ahead of print]
34. G. Pineton de Chambrun, L. Peyrin-Biroulet, M. Lémann, and J.-F. Colombel Clinical implications of mucosal healing for the management of IBD Nat Rev Gastroenterol Hepatol 7 2010 15 29
35. G. D'Haens, K. Geboes, and P. Rutgeerts Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine Gastrointest Endosc 50 1999 667 671
36. D. Laharie, A. Reffet, G. Belleannée, E. Chabrun, C. Subtil, and S. Razaire et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab Aliment Pharmacol Ther 33 2011 714 721
37. J.F. Colombel, W.J. Sandborn, W. Reinisch, G.J. Mantzaris, A. Kornbluth, and D. Rachmilewitz et al. Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
38. C. Zallot, and L. Peyrin-Biroulet Deep remission in inflammatory bowel disease: looking beyond symptoms Curr Gastroenterol Rep 15 2013 315
39. J.-F. Colombel, P.J. Rutgeerts, W.J. Sandborn, M. Yang, A. Camez, and P.F. Pollack et al. Adalimumab induces deep remission in patients with Crohn's disease Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 12 2014 414-422.e5
40. Colombel JF, Reinish W, Mantzaris G, Kombluth A, Oortwijn A, Bevelander S. Composite remission measures in early Crohn's disease: a post-hoc analysis of the SONIC trial. n.d.
41. G.R. Lichtenstein, S. Yan, M. Bala, M. Blank, and B.E. Sands Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease Gastroenterology 128 2005 862 869
42. P.B. Allen, and L. Peyrin-Biroulet Moving towards disease modification in inflammatory bowel disease therapy Curr Opin Gastroenterol 29 2013 397 404
43. C. Zallot, and L. Peyrin-Biroulet Clinical risk factors for complicated disease: how reliable are they? Dig Dis Basel Switz 30 Suppl. 3 2012 67 72
44. L. Peyrin-Biroulet, V. Billioud, G. D'Haens, R. Panaccione, B. Feagan, and J. Panés et al. Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process Am J Gastroenterol 107 2012 1770 1776
45. G. D'Haens, F. Baert, G. Van Assche, P. Caenepeel, P. Vergauwe, and H. Tuynman et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial Lancet 371 2008 660 667
46. B.G. Feagan, J.W.D. McDonald, R. Panaccione, R.A. Enns, C.N. Bernstein, and T.P. Ponich et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease Gastroenterology 146 2014 681-688.e1
47. J.S. Smolen, P. Emery, R. Fleischmann, R.F. van Vollenhoven, K. Pavelka, and P. Durez et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial Lancet 383 2014 321 332
48. R. Khanna, and B.G. Feagan Early combined immunosuppression for the management of Crohn's disease: a community-based cluster randomized trial OP004 ECCO 2014 n.d
49. G.R. Lichtenstein, B.G. Feagan, R.D. Cohen, B.A. Salzberg, R.H. Diamond, and W. Langholff et al. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ registry Am J Gastroenterol 109 2014 212 223
50. C.J.M. Williams, L. Peyrin-Biroulet, and A.C. Ford Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease Aliment Pharmacol Ther 39 2014 447 458
51. M.T. Osterman, W.J. Sandborn, J.-F. Colombel, A.M. Robinson, W. Lau, and B. Huang et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease Gastroenterology 146 2014 941-949.e2
52. G.R. Burmester, R. Panaccione, K.B. Gordon, M.J. McIlraith, and A.P.M. Lacerda Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease Ann Rheum Dis 72 2013 517 524
53. M.D. Long, H.H. Herfarth, C.A. Pipkin, C.Q. Porter, R.S. Sandler, and M.D. Kappelman Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 8 2010 268 274
54. X. Mariette, A.V. Reynolds, and P. Emery Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors Ann Rheum Dis 71 2012 e2
55. F. Magro, L. Peyrin-Biroulet, H. Sokol, X. Aldeger, A. Costa, and P.D. Higgins et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III) J Crohns Colitis 8 2014 31 44
56. G.R. Lichtenstein, B.G. Feagan, R.D. Cohen, B.A. Salzberg, R.H. Diamond, and D.M. Chen et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry Clin Gastroenterol Hepatol 4 2006 621 630
57. P. Deepak, H. Sifuentes, M. Sherid, D. Stobaugh, Y. Sadozai, and E.D. Ehrenpreis T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study Am J Gastroenterol 108 2013 99 105
58. M.E. Van der Valk, M.-J.J. Mangen, M. Leenders, G. Dijkstra, A.A. van Bodegraven, and H.H. Fidder et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study Gut 63 2014 72 79
59. G.R. Lichtenstein, S.B. Hanauer, and W.J. Sandborn Management of Crohn's disease in adults Am J Gastroenterol 104 2009 465 483
60. A. Dignass, G. Van Assche, J.O. Lindsay, M. Lémann, J. Söderholm, and J.F. Colombel et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management J Crohns Colitis 4 2010 28 62
61. B. Pariente, L. Peyrin-Biroulet, L. Cohen, A.-M. Zagdanski, and J.-F. Colombel Gastroenterology review and perspective: the role of cross-sectional imaging in evaluating bowel damage in Crohn disease AJR Am J Roentgenol 197 2011 42 49
62. K.T. Thia, W.J. Sandborn, W.S. Harmsen, A.R. Zinsmeister, and E.V. Loftus Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort Gastroenterology 139 2010 1147 1155
63. L. Peyrin-Biroulet, E.V. Loftus Jr., J.-F. Colombel, and W.J. Sandborn The natural history of adult Crohn's disease in population-based cohorts Am J Gastroenterol 105 2010 289 297
64. L. Peyrin-Biroulet, G. Fiorino, A. Buisson, and S. Danese First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol 10 2013 345 351
65. C. Loly, J. Belaiche, and E. Louis Predictors of severe Crohn's disease Scand J Gastroenterol 43 2008 948 954
66. I.C. Solberg, M.H. Vatn, O. Høie, N. Stray, J. Sauar, and J. Jahnsen et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study Clin Gastroenterol Hepatol 5 2007 1430 1438
67. N. Williet, W.J. Sandborn, and L. Peyrin-Biroulet Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease Clin Gastroenterol Hepatol 2014 Feb 15 pii: S1542-3565(14)00237-7. http://dx.doi.org/10.1016/j.cgh.2014.02.016. [Epub ahead of print]